Addex Therapeutics Ltd (ADXN) Balance Sheet

NASDAQ: ADXNAssets, liabilities, debt and equity over 10 years.

ADXN balance sheet, 2025

December 31, 2025 · Swiss francs

CHF 6.4M assets = CHF 1.6M liabilities + CHF 4.8M equity

What it ownsCHF 6.4MCash & ST investments: CHF 1.6M (25.8%)Cash & ST investmentsCHF 1.6M · 26%Receivables: CHF 20,109 (0.3%)Other current: CHF 16,315 (0.3%)PP&E: CHF 34,275 (0.5%)LT investments: CHF 4.1M (64.9%)LT investmentsCHF 4.1M · 65%Other non-current: CHF 521,437 (8.2%)CHF 521,437=How it is financedCHF 6.4MCurrent liabilities: CHF 1.2M (18.9%)Current liabilitiesCHF 1.2M · 19%Other LT liabilities: CHF 399,068 (6.3%)CHF 399,068Shareholders’ equity: CHF 4.8M (74.9%)Shareholders’ equityCHF 4.8M · 75%

Both columns are drawn to the same scale: what ADXN owns equals what it owes plus shareholders’ equity. Hover a block for its value.

ADXN financial health

Current ratio1.40
Adequate · current assets cover current liabilities 1.40×
Debt / equity0.01
Low leverage · CHF 0.01 of debt for each $1 of equity
Equity / assets74.9%
Equity-funded · of assets funded by shareholders
Cash / debt4,723.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

ADXN balance sheet trends, 2016–2025

Addex Therapeutics Ltd balance sheet trends
MetricTrendThenLatestChange
Total assetsCHF 1.7M2016CHF 6.4M2025+15.9%/yr
Total liabilitiesCHF 1.5M2016CHF 1.6M2025+1.0%/yr
Shareholders’ equityCHF 218,5922016CHF 4.8M2025+40.8%/yr
Cash & short-term investmentsCHF 1.4M2016CHF 1.6M2025+1.6%/yr
Total debtCHF 10,9792017CHF 34,7272025+15.5%/yr
Net cash (debt)CHF 2.6M2017CHF 1.6M2025CHF 973,815
Working capitalCHF 408,6222016CHF 476,5712025CHF 67,949
Current ratio1.3320161.402025+0.07
Debt / equity0.0120170.0120250.00
Shares outstanding95K2016935K2025+28.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ADXN assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

ADXN liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

ADXN debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

ADXN balance sheet in Swiss francs

Addex Therapeutics Ltd annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investmentsCHF 1.6MCHF 3.3MCHF 3.9MCHF 7.0MCHF 20.5MCHF 18.8MCHF 31.6MCHF 41.7MCHF 2.6MCHF 1.4M
Cash & equivalentsCHF 1.6MCHF 3.3MCHF 3.9MCHF 7.0MCHF 20.5MCHF 18.7MCHF 31.5MCHF 41.7MCHF 2.6MCHF 1.4M
Short-term investmentsCHF 5,130CHF 6,496CHF 848CHF 3,165CHF 17,145CHF 64,930CHF 13,968CHF 7,983CHF 11,291—
ReceivablesCHF 20,109CHF 15,513CHF 151,268CHF 598,316CHF 324,421CHF 68,373CHF 118,028CHF 273,016CHF 303,882CHF 220,723
InventoryCHF 0CHF 0CHF 0−CHF 871.6MCHF 1CHF 162,839−CHF 13,968CHF 0CHF 1CHF 0
Other current assetsCHF 16,315CHF 177,616CHF 217,008CHF 871.9MCHF 1.1MCHF 498,382CHF 734,031CHF 199,410CHF 158,922CHF 21,435
Total current assetsCHF 1.7MCHF 3.5MCHF 4.2MCHF 7.8MCHF 21.9MCHF 19.5MCHF 32.4MCHF 42.2MCHF 3.1MCHF 1.7M
Property, plant & equipment (net)CHF 34,275CHF 42,709CHF 352,936CHF 398,734CHF 542,100CHF 633,104CHF 570,966CHF 8,868CHF 2,751CHF 17,303
Goodwill & intangible assetsCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 25.5MCHF 0CHF 0CHF 0
Long-term investmentsCHF 4.1MCHF 7.1MCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0
Other non-current assetsCHF 521,437CHF 7,089CHF 54,344CHF 54,355CHF 57,908CHF 59,144CHF 0CHF 54,404CHF 7,087CHF 7,102
Total assetsCHF 6.4MCHF 10.7MCHF 4.6MCHF 8.3MCHF 22.5MCHF 20.2MCHF 33.0MCHF 42.2MCHF 3.1MCHF 1.7M
Liabilities
Accounts payableCHF 603,585CHF 253,290CHF 984,384CHF 1.3MCHF 1.8MCHF 983,545CHF 2.2MCHF 1.1MCHF 383,211CHF 669,678
Short-term debtCHF 7,680CHF 7,306CHF 273,956CHF 286,107CHF 287,698CHF 308,611CHF 373,025CHF 14,921CHF 10,979—
Deferred revenue——CHF 234,978——CHF 820,149CHF 1.1MCHF 212,744CHF 439,022—
Total current liabilitiesCHF 1.2MCHF 802,093CHF 2.9MCHF 3.3MCHF 4.1MCHF 3.6MCHF 5.7MCHF 2.3MCHF 1.5MCHF 1.2M
Long-term debtCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 177,220CHF 0CHF 0CHF 0
Lease obligationsCHF 34,688CHF 41,994CHF 344,336CHF 373,135CHF 482,014CHF 567,396CHF 550,245———
Other long-term liabilitiesCHF 399,068CHF 198,939CHF 603,136CHF 87,028CHF 1.5MCHF 2.0MCHF 1.6MCHF 639,351CHF 243,864CHF 214,435
Total liabilitiesCHF 1.6MCHF 1.0MCHF 3.5MCHF 3.4MCHF 5.6MCHF 5.6MCHF 7.5MCHF 3.0MCHF 1.7MCHF 1.5M
Shareholders' equity
Common stock & paid-in capitalCHF 2.2MCHF 1.8MCHF 1.8MCHF 1.2MCHF 49.3MCHF 32.8MCHF 32.8MCHF 28.6MCHF 13.4MCHF 11.6M
Retained earnings (deficit)−CHF 360.5M−CHF 353.4M−CHF 360.4M−CHF 349.9M−CHF 329.1M−CHF 313.7M−CHF 300.8M−CHF 286.1M−CHF 284.4M−CHF 281.1M
Accumulated other comprehensive incomeCHF 96.5MCHF 31.1MCHF 29.8MCHF 25.8MCHF 24.4MCHF 14.7MCHF 7.1MCHF 10.3MCHF 7.5MCHF 6.8M
Total shareholders' equityCHF 4.8MCHF 9.7MCHF 1.1MCHF 4.9MCHF 16.9MCHF 14.6MCHF 25.5MCHF 39.2MCHF 1.3MCHF 218,592
Key figures
Total debtCHF 34,727CHF 41,994CHF 344,336CHF 373,135CHF 482,014CHF 567,396CHF 550,245CHF 14,921CHF 10,979—
Net cash (debt)CHF 1.6MCHF 3.3MCHF 3.5MCHF 6.6MCHF 20.0MCHF 18.2MCHF 31.0MCHF 41.7MCHF 2.6M—
Working capitalCHF 476,571CHF 2.7MCHF 1.3MCHF 4.5MCHF 17.8MCHF 15.9MCHF 26.7MCHF 39.8MCHF 1.6MCHF 408,622
Tangible book valueCHF 4.8MCHF 9.7MCHF 1.1MCHF 4.9MCHF 16.9MCHF 14.6MCHF 0CHF 39.2MCHF 1.3MCHF 218,592
Shares outstanding935K818K619K377K284K222K220K194K108K95K
Current ratio1.404.421.462.395.315.385.7018.062.071.33
Quick ratio1.384.191.392.305.045.205.5717.981.961.31
Debt / equity0.010.000.300.080.030.040.020.000.01—
Equity / assets74.9%90.6%24.7%59.3%75.1%72.4%77.3%93.0%43.8%13.0%

Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported (latest annual report filed May 15, 2026); data from EODHD.

ADXN financial position

At the end of fiscal 2025 (December 31, 2025), Addex Therapeutics had total assets of CHF 6.4 million (down 40.4% from a year earlier), total liabilities of CHF 1.6 million and shareholders' equity of CHF 4.8 million. It held CHF 1.6 million in cash and short-term investments against CHF 0.0 million of debt, a net cash position of CHF 1.6 million. Its current ratio was 1.40. In the latest quarter (ended June 30, 2026) total assets were CHF 3.5 million and equity CHF 1.9 million.

Related: ADXN income statement, ADXN cash flow statement, ADXN key metrics. See the ADXN stock overview for the latest quote and news.

ADXN balance sheet FAQ

What are Addex Therapeutics's total assets?

Addex Therapeutics reported total assets of CHF 6.4 million at the end of fiscal 2025 (December 31, 2025), compared with CHF 10.7 million a year earlier.

How much debt does Addex Therapeutics have?

Addex Therapeutics had CHF 0.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.

How much cash does Addex Therapeutics have?

Addex Therapeutics held CHF 1.6 million in cash and short-term investments at the end of fiscal 2025; with CHF 0.0 million of debt that is net cash of CHF 1.6 million.

What is Addex Therapeutics's book value?

Addex Therapeutics's shareholders' equity (book value) was CHF 4.8 million at the end of fiscal 2025.

What is Addex Therapeutics's current ratio?

Addex Therapeutics had current assets of CHF 1.7 million and current liabilities of CHF 1.2 million, a current ratio of 1.40 (it can cover its short-term obligations).

Biotechnology: balance sheet